Nevertheless, it is tempting to speculate that a short-term application of MALT1 inhibitors in combination with immune checkpoint inhibitors could support the T cell-mediated anti-tumor reaction and thus prove beneficial for cancer patients. Here, MALT1 is linked to cancer.